Top

Published in:

01-04-2015 | Research

Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer

Authors: Branka Petrić Miše, Vesna Dobrić Telesmanić, Snježana Tomić, Dinka Šundov, Vesna Čapkun, Eduard Vrdoljak

Published in: Pathology & Oncology Research | Issue 2/2015

Abstract

To analyze correlation between immunoexpression of E-cadherin and efficacy of first line platinum-based chemotherapy in patients with advanced-stage high-grade serous ovarian carcinoma. The expression of E-cadherin was analyzed immunohistochemically in formalin-fixed, paraffin-embedded samples from 98 patients with advanced-stage high-grade serous ovarian cancer and related to clinical features (stage according to the International Federation of Gynecology and Obstetrics (FIGO) and residual tumors after initial cytoreductive surgery), response to platinum-based chemotherapy (according to Response Evaluation Criteria in Solid tumors (RECIST 1.1 criteria)), platinum sensitivity (according to platinum free interval (PFI) as platinum-refractory, platinum-resistant and platinum-sensitive) and patients progression free survival (PFS) and overall survival (OS). E-cadherin immunostaining was positive in 74 and negative in 24 serous ovarian carcinomas. E-cadherin immunoreactivity was not associated with FIGO stage, residual tumor after initial cytoreductive surgery and number of chemotherapy cycles. Positive E-cadherin expression predict significantly better response to first line platinum-based chemotherapy (p < 0.001) and platinum sensitivity (p < 0.001). Moreover, positive E-cadherin expression predict significantly longer PFS (p < 0.001) and OS (p < 0.001). The multivariate analysis for OS showed that positive E-cadherin expression is predictor to platinum sensitivity (p < 0.001) and longer OS (p = 0.01). Positive E-cadherin expression seems to be a predictor of better response to first line platinum-based chemotherapy, platinum sensitivity and favorable clinical outcome in patients with advanced-stage serous ovarian cancer. Negative E-cadherin expression was shown to be significant, independent predictor of poorer PFS and OS. E-cadherin as a marker has predictive and prognostic value.

Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed on 26/May/2014

Carter JS, Downs LS Jr (2011) Ovarian cancer test and treatment. Female Patient (Parsippany) 36:30–35

SEER Cancer Statistics Factsheets: Ovary Cancer. National Cancer Institute. Bethesda, MD,http://seer.cancer.gov/statfacts/html/ovary.html (http://seer.cancer.gov/statfacts/html/ovary.html). Date of access: 26/May/2014

Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: resent advances. Hum Pathol 40:1213–1223. doi:10.1016/j.humpath.2009.04.017 CrossRefPubMed

Helleman J, van Staveren IL, Dinjens WN et al (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6:201. doi:10.1186/1471-2407-6-201 CrossRefPubMedCentralPubMed

Kim A, Ueda Y, Naka T et al (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31:14. doi:10.1186/1756-9966-31-14 CrossRefPubMedCentralPubMed

Bagnato A, Rosano L (2012) Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Curr Oncol 19:36–38. doi:10.3747/co.19.895 CrossRefPubMedCentralPubMed

Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428. doi:10.1038/nrc2644 CrossRefPubMedCentralPubMed

Martin LP, Hamilton TC, Schilder RJ et al (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291–1295. doi:10.1158/1078-0432.CCR-07-2238 CrossRefPubMed

10.

Stewart DJ (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63:12–31. doi:10.1016/j.critrevonc.2007.02.001 CrossRefPubMed

11.

Rosano L, Cianfrocca R, Spinella F (2011) Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17:2350–2360. doi:10.1158/1078-0432.CCR-10-2325 CrossRefPubMed

12.

Baribeau S, Chaudhry P, Parent S et al (2014) Resveratrol inhibits cisplatin-induced epithelial to mesenchymal transition in ovarian cancer cells lines. PLoS One 9:e86987. doi:10.1371/journal.pone.0086987 CrossRefPubMedCentralPubMed

13.

Pećina-Šlaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17. doi:10.1186/1475-2867-3-17 PubMedCentralPubMed

14.

Putzke AP, Ventura AP, Bailey AM et al (2011) Metastatic progression of prostate cancer and E-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 179:400–410. doi:10.1016/j.ajpath.2011.03.028 CrossRefPubMedCentralPubMed

15.

Luber B, Deplazes J, Keller G et al (2011) Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11:509. doi:10.1186/1471-2407-11-509 CrossRefPubMedCentralPubMed

16.

Dong HM, Liu G, Hou YF et al (2007) Dominant negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. J Cancer Res Clin Oncol 133:83–92. doi:10.1007/s00432-006-0140-6 CrossRefPubMed

17.

Ye Y, Tellez JD, Durazo M et al (2010) E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer due to altered trafficking. Anticancer Res 30:3903–3910PubMed

18.

Bačić B, Haller H, Mrklić I et al (2013) Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. Arch Gynecol Obstet 287:1219–1224. doi:10.1007/s00404-012-2684-9 CrossRefPubMed

19.

Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed uniflying theory. Am J Surg Pathol 34:433–443. doi:10.1097/PAS.0b013e3181cf3d79

20.

Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486. doi:10.1093/jnci/95.6.484 CrossRefPubMed

21.

Kurman RJ, Visvanathan K, Roden R et al (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351–356. doi:10.1016/j.ajog.2008.01.005 CrossRefPubMedCentralPubMed

22.

Cho KR, Shih IeM (2009) Ovarian cancer. Annu Rev Pathol 4:287–313. doi:10.1146/annurev.pathol.4.110807.092246

23.

Prat J, FIGO Committee on Gynecologic Oncology (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124:1–5. doi:10.1016/j.ijgo.2013.10.001 CrossRefPubMed

24.

Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504CrossRefPubMed

25.

Wimberger P, Wehling M, Lehmann N et al (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an explratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17:1642–1648. doi:10.1245/s10434-010-0964-9 CrossRefPubMed

26.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026 CrossRefPubMed

27.

Peng HL, He L, Zhao X (2012) Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis – results of meta-analysis. Asian Pac J Cancer Prev 13:2003–2007. doi:10.7314/APJCP.2012.13.5.2003 CrossRefPubMed

28.

Blechschmidt K, Sassen S, Schmalfeldt B et al (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 98:489–495. doi:10.1038/sj.bjc.6604115 CrossRefPubMedCentralPubMed

29.

Cho EY, Choi Y, Chae SW et al (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 56:62–70. doi:10.1111/j.1440-1827.2006.01925.x CrossRefPubMed

30.

Daraï E, Scoazec JY, Walker-Combrouze F et al (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28:922–928CrossRefPubMed

31.

Dian D, Brüning A, Mylonas I (2011) E-cadherin as prognostic marker in human serous carcinomas of the ovary: an immunohistichemical analysis. Arch Gynecol Obstet 284:437–443. doi:10.1007/s00404-010-1657-0 CrossRefPubMed

32.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D et al (2004) Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 15:1535–1542. doi:10.1093/annonc/mdh387 CrossRefPubMed

33.

Ho CM, Cheng WF, Lin MC et al (2010) Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 20:1490–1497. doi:10.1111/IGC.0b013e3181e68a4d PubMed

34.

Bodnar L, Stanczak A, Cierniak S et al (2014) WNT/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovar Res 7:16. doi:10.1186/1757-2215-7-16 CrossRef

35.

Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200. doi:10.1200/JCO.2003.02.153 CrossRefPubMed

36.

du Bois A, Lück HJ, Meier W et al (2003) A randomised clinical trial of cisplatin/paclitaxel versus carboplatin/paclitacel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329. doi:10.1093/jnci/djg036 CrossRefPubMed

37.

McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6. doi:10.1056/NEMJ199601043340101 CrossRefPubMed

38.

Cardoso F, Piccart-Gebhart M, Van’t Veer L et al (2007) The MINDAC trial: the first prospective clinical validation of a genomic tool. Mol Oncol 1:246–251. doi:10.1016/jmolonc.2007.10.004 CrossRefPubMed

39.

Chang JC, Makris A, Gutierrez MC et al (2008) Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in brest cancer patients. Breast Cancer Res Treat 108:233–240. doi:10.1007/s10549-007-9590-2 CrossRefPubMed

40.

Garber K (2010) ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst 102:672–675. doi:10.1093/jnci/djq184 CrossRefPubMed

41.

Lin CC, Yang LC (2011) Optimal management with patients with non-small-cell lung cancer and epidermal growth receptor mutations 71:79–88. doi: 10.2165/11587560-000000000-00000

42.

Berx G, van Roy F (2009) Involvement of members of cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1:a003129. doi:10.1101/cshperspect.a003129 CrossRefPubMedCentralPubMed

43.

Rodriguez FJ, Lewis-Tuffin L, Anastasiadis PZ (2012) E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta 1826:23–31. doi:10.1016/j.bbcan.2012.03.002 PubMedCentralPubMed

44.

Koo JS, Jung W, Jeong J (2009) The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple negative breast cancer. Jpn J Clin Oncol 39:560–568. doi:10.1093/jjco/hyp065 CrossRefPubMed

45.

Fricke E, Hermannstadter C, Keller G et al (2004) Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide and 5-fluorouracile. Oncology 66:105–109. doi:10.1159/000077442 CrossRef

46.

Hofmann G, Balić M, Dandachi N et al (2013) The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy. Clin Biochem 46:1585–1589. doi:10.1016/j.clinbiochem.2013.06.010 CrossRefPubMed

47.

Nakamoto K, Nagahara H, Maeda K et al (2013) Expression of E-cadherin and KRAS mutation may serve as biomarkers in cetuximab-based therapy in metastatic colorectal cancer. Oncol Lett 5:1295–1300. doi:10.3892/ol.2013.1187 PubMedCentralPubMed

48.

Witta SE, Gemmill RM, Hirsch FR et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944–950. doi:10.1158/0008-5472.CAN-05-1988 CrossRefPubMed

49.

Ravi V, Yang J, Araujo DM et al. (2011) The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. J Clin Oncol 29 suppl:abstr 10096

50.

Graziano F, Mandolesi A, Ruzzo A et al (2004) Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol 25:106–110CrossRefPubMed

51.

Spreafico A, Gregorc V, Dziadziuszko R et al. (2007) Serum E-cadherin does not associate with response to gefitinib in patients with non-small cell lung cancer (NSCLC): P3-088. J Thorac Oncol 2:pS716. doi: 10.1097/01.JTO.0000284064.64727.66

52.

Shim HS, Yoon BS, Cho NH (2009) Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol 40:693–698. doi:10.1016/j.humpath.2008.10.013 CrossRefPubMed

53.

Voutilainen KA, Anttila MA, Sillanpää SM et al (2006) Prognostic significance od E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 59:460–467. doi:10.1136/jcp.2005.029876 CrossRefPubMedCentralPubMed

54.

Huang KJ, Sui LH (2012) The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 29:318–323. doi:10.1007/s12032-010-9817-4 CrossRefPubMed

Title: Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer
Authors: Branka Petrić Miše
Vesna Dobrić Telesmanić
Snježana Tomić
Dinka Šundov
Vesna Čapkun
Eduard Vrdoljak
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9827-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver

A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin

Identification of Differently Expressed Genes with Specific SNP Loci for Breast Cancer by the Integration of SNP and Gene Expression Profiling Analyses

Hybrid Odontogenic Tumors: A Controversy

Apoptotic Effects of Quercitrin on DLD-1 Colon Cancer Cell Line

Keynote webinar | Spotlight on antibody–drug conjugates in cancer